Please assess the completion status of the following clinical trial:

Trial Title: Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men age 35 or older~* Primary total hip and knee arthroplasty patients (general, spinal, or epidural anesthesia~* No current use (\>1 month) of alpha-blockers~* Community ambulator~* Adequate organ and marrow function as defined below:~leucocytes at least 3,000/µL, absolute neutrophil count at least 1,500/µL, platelets at least 100,000/µL, creatinine within normal institutional limits~* Ability to understand, and the willingness to sign, a written informed consent~Exclusion Criteria:~* History of radical prostatectomy~* Receiving any other investigational agents~* Revision hip and knee arthroplasty patients~* Severe liver or kidney disease~* Taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir, or conivaptan)~* Being on alpha-blockers (alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, phenoxybenzamine, or silodosin)~* Being of 5-alpha reductase inhibitors (finasteride, dutasteride)~* History of allergy or sensitivity to tamsulosin or other alpha-blockers (alfuzosin, doxazosin, prazosin, terazosin, or phenoxybenzamine)~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Taking Sildenafil,Tadalafil, or Vardenafil

- Gender: MALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tamsulosin (Type: EXPERIMENTAL): 0.4 mg daily for five days pre-op through post-op day one (seven total)
- placebo (Type: PLACEBO_COMPARATOR): One capsule daily for five days pre-op through post-op day one (seven total)

Based on this trial design, predict the completion outcome and termination type (if applicable).